Skip to main content
Cloudbreak Pharma Inc. logo

Cloudbreak Pharma Inc. — Investor Relations & Filings

Ticker · 2592 ISIN · KYG2215S1084 HKEX Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2592

About Cloudbreak Pharma Inc.

https://cloudbreakpharma.com/

Cloudbreak Pharma Inc. is an innovative, clinical-stage ophthalmology biotechnology company dedicated to the research and development of novel and differentiated treatments for chronic eye diseases. The company focuses on improving vision quality globally by developing therapies for both anterior and posterior segment ophthalmic conditions. Its robust pipeline includes products targeting pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, age-related macular degeneration, and diabetic retinopathy. Cloudbreak utilizes advanced platforms, including a potent multi-kinase inhibitor formulated as a topical eye drop for anterior segment diseases and a unique Antibody-Drug Synergism Platform for posterior segment diseases.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR ANNUAL GENERAL MEETING TO BE HELD ON 26 JUNE 2026 (OR AT ANY ADJOURNMENT THEREOF)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy form used to solicit votes and appoint proxies for the Annual General Meeting to be held on 26 June 2026. It is part of the proxy materials provided to shareholders for voting, which falls under proxy solicitation materials. This matches the Proxy Solicitation & Information Statement category.
2026-05-22 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a formal notice convening the annual general meeting, outlining the meeting agenda, resolutions to be voted on, and proxy appointment instructions. It is sent to shareholders to provide information and solicit votes (include proxy details), matching the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-22 English
(1) PROPOSED GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING SALE OR TRANSFER OF TREASURY SHARES); (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a shareholder circular issued in connection with the Annual General Meeting, containing the Notice of AGM, explanatory statements on share repurchase and issue mandates, details of retiring directors, and the form of proxy. It is a solicitation of shareholder votes and information for the meeting, matching the definition of a Proxy Solicitation & Information Statement rather than the AGM presentation itself or a full annual report.
2026-05-22 English
CHANGE IN THE USE OF PROCEEDS
Capital/Financing Update Classification · 85% confidence The document is a formal announcement on the Hong Kong Exchange regarding the Company’s change in the use of IPO/global offering proceeds. It details original and revised allocations of net proceeds, reasons for reallocation, and internal control policies for fund usage. This is not a full financial report, board change notice, voting results, or legal proceeding. Instead, it is a capital/financing update about how the Company will deploy its fundraising proceeds, matching the definition of a Capital/Financing Update (CAP).
2026-05-22 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE IN RELATION TO SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CBT-358
Regulatory Filings Classification · 85% confidence The document is a voluntary business update announcement by Cloudbreak Pharma Inc. concerning the submission of an Investigational New Drug application. It contains no financial statements, management changes, share issuances, voting results, or other specific events that map to the listed categories. It is a miscellaneous regulatory announcement filed on the Hong Kong Exchange. Therefore the best fit is Regulatory Filings (RNS).
2026-05-22 English
POSTPONEMENT OF THE ANNUAL GENERAL MEETING
Regulatory Filings Classification · 82% confidence The document is an announcement by Cloudbreak Pharma notifying shareholders that the Annual General Meeting (AGM) originally scheduled for 29 May 2026 has been postponed to 26 June 2026. It does not contain AGM materials or minutes, financial data, management changes, vote results, or proxy forms. It is a miscellaneous regulatory announcement regarding meeting logistics and does not fit any specialized category such as AGM materials (AGM-R), vote results (DVA), or report filing. Therefore, it falls under the general Regulatory Filings (RNS) category as a fallback.
2026-05-20 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.